Blood test may sharpen endometrial cancer risk prediction

NCT ID NCT07746024

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current staging system, researchers hope to better identify which patients are at higher risk and may need more intensive follow-up or treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Liquid biopsy (blood test for circulating tumor DNA and proteins)
What this could lead to
If successful, this could lead to a more precise way to predict endometrial cancer recurrence, helping tailor follow-up and treatment to each patient's risk.
What could go wrong
This is an observational study, so it won't directly test a new treatment. The results may not change practice immediately, and the accuracy of the blood test in real-world settings remains to be seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli, IRCCS

    Roma, 00186, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.